Cardinal Health, Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Cardinal Health Raises 2026 EPS Outlook, Highlights Growth

AI-generated analysis

📈 Cardinal Health raised its fiscal 2026 non-GAAP diluted EPS outlook to at least $10.00 from a prior range of $9.65 to $9.85.

💰 The company projects Specialty revenues will exceed $50 billion in fiscal 2026, reflecting a 16% three-year compounded annual growth rate.

🚀 BioPharma Solutions is expected to see more than 30% anticipated revenue growth driven by robust demand and new platform expansions.

🤝 Cardinal Health secured major patient-support hub wins with Sanofi and Regeneron's Dupixent My Way program.

⚖️ The company successfully transitioned manufacturer distribution service agreements for drugs affected by the 2026 Medicare Drug Price Negotiation Program before the January 1 deadline.

🏥 Cardinal Health launched the ContinuCare Pathway program to streamline diabetes supply delivery through a pharmacy-to-supplier referral model.

📊 The new pharmacy referral model is already adopted by Publix's nearly 1,400 pharmacies and expanding to over 11,000 retail and grocery locations.

👍 Analysts maintain a Buy rating on CAH stock with a price target of $244.00.

Bullish Signals
  • Cardinal Health raised its fiscal 2026 non-GAAP diluted EPS outlook to at least $10.00, up from a prior range of $9.65 to $9.85.
  • The company projects Specialty revenues will exceed $50 billion in fiscal 2026, reflecting a three-year compounded annual growth rate of 16%.
  • BioPharma Solutions is anticipated to grow revenue by more than 30%, driven by robust demand and expansion of management services platforms.
  • Cardinal Health secured major new patient-support hub wins with Sanofi and Regeneron's Dupixent My Way program.
  • The company successfully transitioned manufacturer distribution service agreements for drugs affected by the 2026 Medicare Drug Price Negotiation Program before the January 1 implementation.
  • Cardinal Health launched the ContinuCare Pathway program to streamline diabetes supply delivery, already adopted by Publix's nearly 1,400 pharmacies and expanding to over 11,000 retail and grocery pharmacies.
Full Analysis
On January 13, 2026, Cardinal Health raised its fiscal 2026 non-GAAP diluted earnings per share outlook to at least $10.00, expanding from a previous range of $9.65 to $9.85. The company cited strong performance across all five operating segments and signaled continued operational momentum ahead of a detailed update scheduled for February 5. Cardinal Health projected that its Specialty revenues would exceed $50 billion in fiscal 2026, representing a three-year compounded annual growth rate of 16%. This growth is underpinned by robust demand in specialty distribution and the expansion of its management services organization platforms. Additionally, the company anticipates more than 30% revenue growth in BioPharma Solutions. The healthcare distributor highlighted major new patient-support hub wins, including partnerships with Sanofi and Regeneron's Dupixent My Way program. Cardinal Health also reported successfully transitioning manufacturer distribution service agreements for drugs affected by the 2026 Medicare Drug Price Negotiation Program before the January 1 implementation to preserve compensation. Furthermore, the company launched the ContinuCare Pathway program within its at-Home Solutions business to streamline medical-benefit diabetes supply delivery. This new pharmacy-to-supplier referral model has already been adopted by Publix's nearly 1,400 pharmacies and is expanding to over 11,000 retail and grocery pharmacies.